BLOOD RESEARCH Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2288-0011   pISSN 2287-979X

 

Cited by CrossRef (44)

  1. Eric Tse, Rex Au-Yeung, Yok-Lam Kwong. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. Expert Review of Hematology 2019;12:927
    https://doi.org/10.1080/17474086.2019.1660640
  2. Vadim S. Pokrovsky, Denis Vinnikov. Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion. Expert Review of Anticancer Therapy 2019;19:93
    https://doi.org/10.1080/14737140.2019.1549992
  3. S.H. Lim, J.Y. Hong, S.T. Lim, H. Hong, J. Arnoud, W. Zhao, D.H. Yoon, T. Tang, J. Cho, S. Park, Y.H. Ko, S.J. Kim, C. Suh, T. Lin, W.S. Kim. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Annals of Oncology 2017;28:2199
    https://doi.org/10.1093/annonc/mdx316
  4. Zihang Chen, Pujun Guan, Tong Shan, Yunxia Ye, Limin Gao, Zhi Wang, Sha Zhao, Wenyan Zhang, Li Zhang, Ling Pan, Weiping Liu. CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis. Oncotarget 2018;9:16547
    https://doi.org/10.18632/oncotarget.24044
  5. John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer. Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions. JCM 2022;11:2699
    https://doi.org/10.3390/jcm11102699
  6. Christian Münz. New Drug Development for Known and Emerging Viruses. 2022.
    https://doi.org/10.1002/9783527810697.ch7
  7. Yanfen Feng, Huilan Rao, Yiyan Lei, Yuhua Huang, Fang Wang, Yu Zhang, Shaoyan Xi, Qiuliang Wu, Jianyong Shao. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. Chin J Cancer 2017;36
    https://doi.org/10.1186/s40880-017-0212-9
  8. Boyu Hu, Yasuhiro Oki. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. Front. Oncol. 2018;8
    https://doi.org/10.3389/fonc.2018.00139
  9. Motoko Yamaguchi, Masahiko Oguchi, Ritsuro Suzuki. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Practice & Research Clinical Haematology 2018;31:315
    https://doi.org/10.1016/j.beha.2018.07.002
  10. U. Wehkamp, M. Weichenthal. Therapie seltener kutaner T‑Zell-Lymphome und der blastären plasmazytoiden dendritischen Zellneoplasie. Hautarzt 2017;68:711
    https://doi.org/10.1007/s00105-017-4024-2
  11. Carrie Van Der Weyden, Michael Dickinson, James Whisstock, H. Miles Prince. Brentuximab vedotin in T-cell lymphoma. Expert Review of Hematology 2019;12:5
    https://doi.org/10.1080/17474086.2019.1558399
  12. Shaoxuan Hu, Ningjing Lin, Jiaxin Liu, Yan Sun, Weiping Liu, Xiaopei Wang, Yan Xie, Yuqin Song, Yi Wen, Jun Zhu. A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma. Front. Oncol. 2022;12
    https://doi.org/10.3389/fonc.2022.839252
  13. Kamel Laribi, Mustapha Alani, Catherine Truong, Alix Baugier de Materre. Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. 2018;23:1039
    https://doi.org/10.1634/theoncologist.2017-0524
  14. Eric Tse, Yok-Lam Kwong. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol 2017;10
    https://doi.org/10.1186/s13045-017-0452-9
  15. Jian‐Chao Wang, Xue‐Qin Deng, Wei‐Ping Liu, Li‐Min Gao, Wen‐Yan Zhang, Jia‐Qi Yan, Yun‐Xia Ye, Feng Liu, Sha Zhao. Comprehensive Flow‐Cytometry‐Based Immunophenotyping Analysis for Accurate Diagnosis and Management of Extranodal NK/T Cell Lymphoma, Nasal Type. Cytometry 2020;98:28
    https://doi.org/10.1002/cyto.b.21838
  16. U. Wehkamp, M. Weichenthal. Therapie seltener kutaner T‑Zell-Lymphome und der blastären plasmazytoiden dendritischen Zellneoplasie. best practice onkologie 2017;12:316
    https://doi.org/10.1007/s11654-017-0052-8
  17. Shinichi Makita, Kensei Tobinai. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma. Hematology/Oncology Clinics of North America 2017;31:239
    https://doi.org/10.1016/j.hoc.2016.11.007
  18. Eric Tse, Yok-Lam Kwong. Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies. Cancers 2022;14:597
    https://doi.org/10.3390/cancers14030597
  19. Motoko Yamaguchi, Kana Miyazaki. Current treatment approaches for NK/T-cell lymphoma. JCEH 2017;57:98
    https://doi.org/10.3960/jslrt.17018
  20. Jaap A. van Doesum, Anne G. H. Niezink, Gerwin A. Huls, Max Beijert, Arjan Diepstra, Tom van Meerten. Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment. 2021;5:e523
    https://doi.org/10.1097/HS9.0000000000000523
  21. Zhenchang Sun, Wenjuan Wan, Xudong Zhang, Lei Zhang, Xin Li, Ling Li, Xinhua Wang, Feifei Nan, Hui Yu, Yu Chang, Jiaqin Yan, Zhaoming Li, Fangfang Cui, Jurui Ge, Yaqin Duo XiaXu, Xia Xu, Xiaorui Fu, Mingzhi Zhang. The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma. J Cancer Res Clin Oncol 2022
    https://doi.org/10.1007/s00432-022-04203-x
  22. Li-Mei Poon, Yok-Lam Kwong. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Ann Hematol 2016;95:847
    https://doi.org/10.1007/s00277-016-2627-9
  23. Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim. EBV-associated NK and T-cell lymphoid neoplasms. 2022;Publish Ahead of Print
    https://doi.org/10.1097/CCO.0000000000000889
  24. Xiaohua He, Yan Gao, Zhiming Li, Huiqiang Huang. Review on natural killer/T‐cell lymphoma. Hematological Oncology 2021
    https://doi.org/10.1002/hon.2944
  25. . Brentuximab-vedotin. Reactions Weekly 2016;1588:58
    https://doi.org/10.1007/s40278-016-14649-x
  26. Eric Tse, Yok-Lam Kwong. NK/T-cell lymphomas. Best Practice & Research Clinical Haematology 2019;32:253
    https://doi.org/10.1016/j.beha.2019.06.005
  27. Seong Hyun Jeong. Extranodal NK/T cell lymphoma. Blood Res 2020;55:S63
    https://doi.org/10.5045/br.2020.S011
  28. Roland Schwarting, Eric Behling, Ashleigh Allen, Vivian Arguello-Guerra, Tulin Budak-Alpdogan. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies. 2022;146:415
    https://doi.org/10.5858/arpa.2021-0338-RA
  29. Eric Tse, Yok-Lam Kwong. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Review of Hematology 2016;9:861
    https://doi.org/10.1080/17474086.2016.1206465
  30. Yi-Jiun Su, Po-Nan Wang, Hung Chang, Lee-Yung Shih, Tung-Liang Lin, Ming-Chung Kuo, Wen-Yu Chuang, Jin-Hou Wu, Tzung-Chih Tang, Yu-Shin Hung, Po Dunn, Hsiao-Wen Kao. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases. Eur J Haematol 2018;101:379
    https://doi.org/10.1111/ejh.13126
  31. Sharmila Ghosh, Jacques Azzi, Amy M. Chan, Kambiz Nael, Anne S. Renteria, Amir Steinberg, Bruce E. Petersen. Primary Extranodal NK/T-Cell Lymphoma Presenting as Neurolymphomatosis Involving Multiple Cranial Nerves: A Case Report. Acta Haematol 2022;145:97
    https://doi.org/10.1159/000518797
  32. Franziska Kampa, Christina Mitteldorf. A review of CD30 expression in cutaneous neoplasms . J Cutan Pathol 2021;48:495
    https://doi.org/10.1111/cup.13894
  33. Chih‐Yi Liu, Bo‐Jung Chen, Shih‐Sung Chuang. Malignant effusions from extranodal NK/T‐cell lymphomas are frequently of anaplastic morphology with azurophilic granules and of T‐cell lineage. Diagnostic Cytopathology 2020;48:453
    https://doi.org/10.1002/dc.24388
  34. Laure Philippe Walter, Lucile Couronné, Jean‐Philippe Jais, Phong‐Dinh Nguyen, Didier Blaise, Arnaud Pigneux, Gérard Socié, Catherine Thieblemont, Emmanuel Bachy, Nathalie Fegueux, Patrice Chevallier, Mohamad Mohty, Ibrahim Yakoub‐Agha, Regis Peffault de Latour, Arnaud Jaccard, Olivier Hermine. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/ T‐Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire ( SFGM‐TC ) . American J Hematol 2021;96:834
    https://doi.org/10.1002/ajh.26200
  35. Azza Ghannem, Amina Aounallah, Mossab Ghannouchi, Nacef Karim, Mohamed Ben Khalifa, Moez Boudokhan, Abdelsayyed Nihed, Sriha Badreddine, Colandane Belajouza, Mohamed Denguezli. Primary cutaneous natural killer/T‐cell lymphoma presenting as sacrococcygeal and perianal ulcers. J Cutan Pathol 2021
    https://doi.org/10.1111/cup.14174
  36. Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang. NK-/T-cell lymphomas. Leukemia 2021;35:2460
    https://doi.org/10.1038/s41375-021-01313-2
  37. Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang. The landscape of new drugs in extranodal NK/T-cell lymphoma. Cancer Treatment Reviews 2020;89:102065
    https://doi.org/10.1016/j.ctrv.2020.102065
  38. Jason Yongsheng Chan, Soon Thye Lim. Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. Int J Hematol 2018;107:413
    https://doi.org/10.1007/s12185-018-2406-6
  39. Susan Swee-Shan Hue, Siok-Bian Ng, Shi Wang, Soo-Yong Tan. Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders. Cancers 2022;14:2483
    https://doi.org/10.3390/cancers14102483
  40. Eric Tse, Wei-Li Zhao, Jie Xiong, Yok-Lam Kwong. How we treat NK/T-cell lymphomas. J Hematol Oncol 2022;15
    https://doi.org/10.1186/s13045-022-01293-5
  41. Kebing Lv, Ting Yin, Min Yu, Zhiwei Chen, Yulan Zhou, Fei Li. Treatment Advances in EBV Related Lymphoproliferative Diseases. Front. Oncol. 2022;12
    https://doi.org/10.3389/fonc.2022.838817
  42. Motoko Yamaguchi, Ritsuro Suzuki, Masahiko Oguchi. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 2018;131:2528
    https://doi.org/10.1182/blood-2017-12-791418
  43. Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. Hematological Oncology 2018;36:166
    https://doi.org/10.1002/hon.2482
  44. Lijun Du, Lei Zhang, Ling Li, Xin Li, Jiaqin Yan, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jingjing Wu, Hui Yu, Yu Chang, Zhiyuan Zhou, Feifei Nan, Xiaolong Wu, Li Tian, Mingzhi Zhang.

    Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

    . OTT 2020;Volume 13:7189
    https://doi.org/10.2147/OTT.S262039